Clinical Trial Update: A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas [Phase 1]

View source ↗

Summary

MIL62 was studied in a Phase 1 trial for CD20-positive B-cell non-Hodgkin lymphoma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• MIL62

Snippet

Sponsor: Beijing Mabworks Biotech Co., Ltd. | Conditions: CD20-positive B Cell Non-Hodgkin Lymphoma | Phase 1 | Status: COMPLETED